Korea approves Samsung Bioepis' Herceptin biosimilar

(Ref: The Korea Herald)
  • South Korea has authorised Samsung Bioepis' Samfenet as a biosimilar of Roche's Herceptin, The Korea Herald reported Thursday.

  • The therapy was officially cleared for treating metastatic breast cancer, early-stage breast cancer and metastatic gastric cancer.

  • Samsung Bioepis plans to launch the therapy after selecting a marketing partner and completing drug pricing procedures.

  • Herceptin generated about $6.8 billion in global revenue last year.

  • Samsung Bioepis previously received clearance for biosimilars referencing Enbrel, Remicade and Humira in Korea.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>